Back
Concentrix Corp. 10K Form
Sell
32
CNXC
Concentrix Corp.
Last Price:
$36.90
Seasonality Move:
4.03%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-10-06 | 10Q | CNXC/Concentrix Corp. Quarterly |
| 2023-07-07 | 10Q | CNXC/Concentrix Corp. Quarterly |
| 2023-04-07 | 10Q | CNXC/Concentrix Corp. Quarterly |
| 2022-10-07 | 10Q | CNXC/Concentrix Corp. Quarterly |
| 2022-07-08 | 10Q | CNXC/Concentrix Corp. Quarterly |
| 2022-04-08 | 10Q | CNXC/Concentrix Corp. Quarterly |
Receive CNXC News And Ratings
See the #1 stock for the next 7 days that we like better than CNXC
CNXC Financial Statistics
Sales & Book Value
| Annual Sales: | $9.6B |
|---|---|
| Cash Flow: | $159.7M |
| Price / Cash Flow: | 4.56 |
| Annual Sales: | $69.83 |
| Price / Book: | 0.53 |
Profitability
| EPS (TTM): | 4.73200 |
|---|---|
| Net Income (TTM): | $301.4M |
| Gross Margin: | $2.7B |
| Return on Equity: | 7.22% |
| Return on Assets: | 2.48% |
Concentrix Corp. Earnings Forecast
Key Concentrix Corp. Financial Ratios
-
The Gross Profit Margin over the past 12 years for CNXC is 28.56%.
-
The Selling, General & Administrative Expenses for CNXC have been equal to 29.66% of Gross Profit Margin.
-
The Interest Expense is 133.14% of Operating Income.
-
The Net Earning history of CNXC is 2.51% of Total Revenues.
-
Per Share Earnings over the last 10 years have been positive in 5 years.
Concentrix Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Professional Services |
| Sector: | Industrials |
| Current Symbol: | CNXC |
| CUSIP: | 20602D |
| Website: | concentrix.com |
Debt
| Debt-to-Equity Ratio: | 1.32 |
|---|---|
| Current Ratio: | 1.56 |
| Quick Ratio: | 1.3 |
Price-to-Earnings
| Trailing P/E Ratio: | 9.95 |
|---|---|
| Forward P/E Ratio: | 2.64 |
CNXC Technical Analysis vs Fundamental Analysis
Sell
32
Concentrix Corp. (CNXC)
is a Sell
Is Concentrix Corp. a Buy or a Sell?
-
Concentrix Corp. stock is rated a SellThe current Concentrix Corp. [CNXC] share price is $36.96. The Score for CNXC is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.